News

Posters and Presentations

AUM 302

Peer Review Publications:

Sean P. Kennedy, Michael O’Neill, Darren Cunningham, Oncogene(2020), 10 February 2020.

Sofie Mohlin, Daniel Bexell, EMBO Molecular Medicine, 16 July 2019.

"Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer"

.Sabina Luszcak, Benjamin S Simpson, et al. Nature Scientific Reports; 1st September 2020.

Poster Presentations:

"Co-targeting PIM kinase to overcome MET amplified resistance to EGFR TKIs in NSCLC"

2019 IASLC World Conference on Lung Cancer, Barcelona, September 7-10, 2019.

"Activation of the MACC1/PIM/cMyc axis confers resistance to PI3K/mTOR inhibition in PIK3CA mutant NSCLC"

2018 AACR Targeting PI3K/mTOR Signaling Conference, November 30-December 3, 2018, Boston MA.

2018 American Association for Cancer Research (AACR) Annual Meeting, April 14-18, 2018 in Chicago.

"Elucidating the Role of PIM Kinase and Its Therapeutic Potential in NSCLC" and "Resistance Mechanisms to PI3K-mTOR Inhibition in NSCLC"

17th IASLC World Conference on Lung Cancer, Vienna, December 4-7, 2016.

International Association of Lung Cancer (IASLC) 16th World Conference on Lung Cancer in Denver, CO September 6-9, 2015.

"Initial Evaluation of Novel Dual PIM/PI3K and Triple PIM/PI3K/MTOR inhibitors in multiple myeloma"

20th Congress of the European Hematology Association (EHA) June 11 – 14, 2015, Vienna.

57th ASH Annual Meeting, Orlando, December 5-8, 2015.

American Association for Cancer Research (AACR) Annual Meeting 2014, April 5-9, San Diego, California.

2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, Boston, USA.